LivaNova (LIVN) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $1.26
- Estimate
- $1.09
- Surprise
- +15.1%
- Revenue (period 2026-06-30)
- $390.6M
- Score today
- 6.4/10
Revenue source: xbrl.
How the report landed
LivaNova (LIVN) beat the $1.09 estimate with adjusted EPS of $1.26 — a large 15.1% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates LIVN Hold at 6.4/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +15.1% surprise compares with a +12.6% four-quarter average. Next scheduled report: 2026-11-04.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong growth profile
What argues against it
- Analyst target reached - limited upside remaining
- Earnings today - binary event risk
- Target reached (-1.4% upside)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $79.90
- Stop
- $75.10
The stock trades at 23.7× trailing but 17.1× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: trading volume is running 1.6× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-11-04 — shown for context, not personalized investment advice.
LIVN at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $4.42B
- P/E (fwd)
- 17.1
- P/E (ttm)
- 23.7
- 52-week range
- $48.82–$85.76
- Off 52-week high
- 6.8%
- RSI (14)
- 63
- Volume vs avg
- 1.63×
- Score today
- 6.4/10